核酸治療薬の市場規模、シェア、成長分析：製品別、適応症別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

核酸治療薬の世界市場規模は2023年に59億米ドルとなり、予測期間（2025-2032年）のCAGRは13.6%で、2024年の67億米ドルから2032年には185億9,000万米ドルに成長する見通しです。

核酸治療薬市場は、がん、てんかん、糖尿病、結核、エイズなどの慢性疾患に対する革新的な治療への関心の高まりによって、急成長を遂げようとしています。DNA、RNA、および合成変異体を含む核酸は、細胞に不可欠な情報を伝達する上で極めて重要であり、その重要な治療用途が認められています。複数の新しい治療法が承認され、開発パイプラインが充実していることから、市場は、特にバイオ医薬品とDNA治療薬における医薬品・ヘルスケア分野の進歩に後押しされ、活況を呈しています。効果的な慢性疾患治療への需要が高まり続け、核酸ベースのソリューションが現代医学の最前線に位置づけられる中、このような状況は利害関係者にとって有望な機会を示しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ分析

核酸治療薬市場規模：製品別& CAGR（2025-2032）

• 市場概要
• アンチセンスオリゴヌクレオチド（ASO）
• RNA干渉（RNAi）
• RNAアプタマー

核酸治療薬市場規模：適応症別& CAGR（2025-2032）

• 市場概要
• 自己免疫疾患
• 感染症
• 遺伝性疾患
• がん
• その他

核酸治療薬市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 診療所
• その他

核酸治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Wave Life Science Ltd.（Singapore）
• Imugene（Australia）
• Aileron Therapeutics Inc.（US）
• BioNTech SE（Germany）
• Protagonist Therapeutics Inc.（US）
• Replicate Bioscience Inc.（US）
• Eli Lilly and Company（US）
• Copernicus Therapeutics Inc.（US）
• Invio Pharmaceuticals Inc.（US）
• Benitec Biopharma（Australia）
• Alnylam Pharmaceuticals（US）
• Zydus Cadila（India）
• Excision BioTherapeutics（US）
• Pfizer Inc.（US）
• Rhythm Pharmaceuticals Inc.（US）
• Axcella Health Inc.（US）

結論と推奨事項

Global Nucleic Acid Therapeutics Market size was valued at USD 5.9 billion in 2023 and is poised to grow from USD 6.7 billion in 2024 to USD 18.59 billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).

The nucleic acid therapeutics market is poised for rapid growth, driven by increased interest in innovative treatments for chronic diseases, including cancer, epilepsy, diabetes, tuberculosis, and AIDS. Nucleic acids, encompassing DNA, RNA, and synthetic variants, are pivotal in conveying essential cellular information and are recognized for their critical therapeutic applications. With multiple new therapies gaining approval and a robust pipeline of developments, the market is experiencing an upswing, fueled by advancements in the pharmaceutical and healthcare sectors, particularly within biopharmaceuticals and DNA therapeutics. This landscape showcases a promising opportunity for stakeholders as the demand for effective chronic disease treatments continues to escalate, positioning nucleic acid-based solutions at the forefront of modern medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nucleic Acid Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nucleic Acid Therapeutics Market Segmental Analysis

Global Nucleic Acid Therapeutics Market is segmented by Product, Indication, End-user and region. Based on Product, the market is segmented into Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi) and RNA Aptamers. Based on Indication, the market is segmented into Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer and Others. Based on End-user, the market is segmented into Hospitals, Physicians' Offices and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is significantly driven by the rapid advancements in molecular technologies and the extensive research in the field of omics. This evolving landscape has prompted numerous companies to intensify their investments as they strive to enhance their competitive edge. As the market evolves, various business strategies, such as acquisitions, partnerships, and collaborations, play a crucial role in capturing market share and generating revenue. A notable example is Merck & Co.'s announcement in August 2022 regarding a collaborative effort with Orna Therapeutics aimed at discovering, developing, and commercializing innovative RNA-based therapies targeting vaccines, infectious diseases, and oncology.

Restraints in the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market faces significant restraints, notably in the area of delivery challenges. A primary obstacle is the effective transport of nucleic acid therapies to their intended target cells, as achieving precise localization while minimizing off-target effects is complex. The intricate nature of nucleic acid compounds often complicates their integration into existing biological systems, leading to potential inefficacies in treatment outcomes. As a result, overcoming these delivery-related issues is crucial for the market's growth, necessitating ongoing research and innovative solutions to enhance the precision and effectiveness of these therapeutic agents in clinical applications.

Market Trends of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is experiencing significant growth, fueled by heightened investments in healthcare services and a growing focus on advanced treatment methodologies. As the prevalence of genetic disorders and chronic illnesses rises, research and development efforts are intensifying, leading to innovative therapeutic solutions leveraging nucleic acids, such as RNA-based therapies and gene editing techniques. This surge in investment is not only accelerating the pace of research but also enhancing health facility capabilities, thereby expanding market opportunities. Additionally, increased collaboration between public and private sectors is facilitating breakthroughs in treatment, positioning nucleic acid therapeutics as a cornerstone in modern medical care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Nucleic Acid Therapeutics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Anti-Sense Oligonucleotides (ASO)
• RNA Interference (RNAi)
• RNA Aptamers

Global Nucleic Acid Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Autoimmune Disorders
• Infectious Diseases
• Genetic Disorders
• Cancer
• Others

Global Nucleic Acid Therapeutics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Physicians' Offices
• Others

Global Nucleic Acid Therapeutics Market Size & CAGR (2025-2032)

• North America (Product, Indication, End-user)
  • US
  • Canada
• Europe (Product, Indication, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Wave Life Science Ltd. (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aileron Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protagonist Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Replicate Bioscience Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Copernicus Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invio Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Benitec Biopharma (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Excision BioTherapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axcella Health Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations